Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0152030 (skin irritation)
 2,146 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present study deals with transdermal drug delivery system (TDDS) of Carvedilol (CRV) and Hydrochlorothiazide (HCTZ). It compares the bioavailability of these two study drugs from a TDDS with conventional immediate release oral tablets in healthy volunteers. The TDDS was also evaluated for any adverse drug reaction. This was an open-label, randomised, single centre, two-treatment, two period, single dose, crossover pilot study of two formulations of cardiovascular agents. Subjects (n=10) were randomised to have a TDDS applied to their abdominal skin for 72h or receive one oral tablet each of CRV and HCTZ respectively in period I, followed by 1-week washout period. They received the alternative treatment in period II. A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets. The TDDS possesses significant potential for skin irritation. The TDDS developed in our laboratory produced therapeutically effective plasma concentrations of the cardiovascular agents up to a range of 60 to 72h (in different volunteers with a mean=66h). It could be concluded from these observations that the TDDS meets the intended goal of at least 2day management of stage II hypertension with application of a single transdermal patch, hence improving patient compliance over the inconvenience seen with frequent oral administration.
 ...
PMID:Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. 2038 72